213 related articles for article (PubMed ID: 22902972)
1. Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe.
Bonhoeffer J; Black S; Izurieta H; Zuber P; Sturkenboom M
Biologicals; 2012 Sep; 40(5):393-7. PubMed ID: 22902972
[TBL] [Abstract][Full Text] [Related]
2. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
Nguyen M; Ball R; Midthun K; Lieu TA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
[TBL] [Abstract][Full Text] [Related]
3. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
4. Monitoring and assessing vaccine safety: a European perspective.
Lopalco PL; Johansen K; Ciancio B; De Carvalho Gomes H; Kramarz P; Giesecke J
Expert Rev Vaccines; 2010 Apr; 9(4):371-80. PubMed ID: 20370548
[TBL] [Abstract][Full Text] [Related]
5. Post-licensure monitoring of HPV vaccine in the United States.
Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
[TBL] [Abstract][Full Text] [Related]
6. The Vaccine Safety Datalink: a model for monitoring immunization safety.
Baggs J; Gee J; Lewis E; Fowler G; Benson P; Lieu T; Naleway A; Klein NP; Baxter R; Belongia E; Glanz J; Hambidge SJ; Jacobsen SJ; Jackson L; Nordin J; Weintraub E
Pediatrics; 2011 May; 127 Suppl 1():S45-53. PubMed ID: 21502240
[TBL] [Abstract][Full Text] [Related]
7. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
[TBL] [Abstract][Full Text] [Related]
8. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010.
Yih WK; Lee GM; Lieu TA; Ball R; Kulldorff M; Rett M; Wahl PM; McMahill-Walraven CN; Platt R; Salmon DA
Am J Epidemiol; 2012 Jun; 175(11):1120-8. PubMed ID: 22582207
[TBL] [Abstract][Full Text] [Related]
9. Preventive medicines: vaccination, prophylaxis of infectious diseases, disinfectants.
Heininger U
Handb Exp Pharmacol; 2011; 205():317-37. PubMed ID: 21882119
[TBL] [Abstract][Full Text] [Related]
10. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program.
Baker MA; Lieu TA; Li L; Hua W; Qiang Y; Kawai AT; Fireman BH; Martin DB; Nguyen MD
Am J Epidemiol; 2015 Apr; 181(8):608-18. PubMed ID: 25769306
[TBL] [Abstract][Full Text] [Related]
11. Health outcomes of interest for evaluation in the Post-Licensure Rapid Immunization Safety Monitoring Program.
Lieu TA; Nguyen MD; Ball R; Martin DB
Vaccine; 2012 Apr; 30(18):2824-30. PubMed ID: 22394993
[TBL] [Abstract][Full Text] [Related]
12. The Vaccine Safety Datalink project.
DeStefano F;
Pharmacoepidemiol Drug Saf; 2001; 10(5):403-6. PubMed ID: 11802585
[TBL] [Abstract][Full Text] [Related]
13. Monitoring vaccine safety using the Vaccine Safety Datalink: utilizing immunization registries for pandemic influenza.
McCarthy NL; Gee J; Weintraub E; Donahue JG; Nordin JD; Daley MF; Naleway A; Henninger M; Baxter R; Crane B; Aukes L; Wagner N; Fisher S; Jacobsen SJ; Sy L; Baggs J
Vaccine; 2011 Jul; 29(31):4891-6. PubMed ID: 21596088
[TBL] [Abstract][Full Text] [Related]
14. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe.
Nicoll A; Ammon A; Amato Gauci A; Ciancio B; Zucs P; Devaux I; Plata F; Mazick A; Mølbak K; Asikainen T; Kramarz P
Public Health; 2010 Jan; 124(1):14-23. PubMed ID: 20141821
[TBL] [Abstract][Full Text] [Related]
15. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.
Lopalco PL; DeStefano F
Vaccine; 2015 Mar; 33(13):1541-8. PubMed ID: 25444788
[TBL] [Abstract][Full Text] [Related]
16. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
[TBL] [Abstract][Full Text] [Related]
17. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA.
Chen RT; DeStefano F; Davis RL; Jackson LA; Thompson RS; Mullooly JP; Black SB; Shinefield HR; Vadheim CM; Ward JI; Marcy SM
Bull World Health Organ; 2000; 78(2):186-94. PubMed ID: 10743283
[TBL] [Abstract][Full Text] [Related]
18. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study.
Velentgas P; Bohn RL; Brown JS; Chan KA; Gladowski P; Holick CN; Kramer JM; Nakasato C; Spettell CM; Walker AM; Zhang F; Platt R
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1226-34. PubMed ID: 18956428
[TBL] [Abstract][Full Text] [Related]
19. Vaccine Safety.
Morris L; Swofford S
Prim Care; 2020 Sep; 47(3):431-441. PubMed ID: 32718441
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on the future of postmarket vaccine safety surveillance and evaluation.
Ball R
Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
